Skip to content

Stop Addiction Stigma

Stop Addiction Stigma Training Workshop With Case Vignettes to Decrease Stigmatizing Attitudes Toward People With Substance Abuse Disorders

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06582030
Enrollment
93
Registered
2024-09-03
Start date
2023-10-17
Completion date
2023-12-31
Last updated
2024-09-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm

Brief summary

This clinical trial evaluates the impact of a Stop Addiction Stigma (SAS) training workshop with a short description of the conditions related to addiction (vignettes) on stigmatizing attitudes toward individuals with substance abuse disorders. Reviews have shown that patients with substance abuse disorders have experienced negative attitudes from their health care providers. Negative attitudes may lead to less involvement from the provider and the patient and may lead to less effective care. Using case vignettes with a SAS workshop may be an effective method to help people learn about addiction, reduce the stigma toward addiction and improve the quality of health care.

Detailed description

PRIMARY OBJECTIVE: I. To describe the impact of SAS training on participants' responses to people with a substance impairment. SECONDARY OBJECTIVES: I. To evaluate the feasibility of stigma training workshops on stigmatizing attitudes health care personnel. II. To explore the maintainability of responses over time. III. To explore relationships between language and stigmatizing attitudes. OUTLINE: Participants are randomized to 1 of 6 group case vignettes. GROUP A (CHRONICALLY RELAPSING BRAIN DISEASE): Participants view the chronically relapsing brain disease vignette and attend a SAS workshop on study. GROUP B (BRAIN DISEASE): Participants view the brain disease vignette and attend a SAS workshop on study. GROUP C (DISEASE): Participants view the disease vignette and attend a SAS workshop on study. GROUP D (ILLNESS): Participants view the illness vignette and attend a SAS workshop on study. GROUP E (DISORDER): Participants view the disorder vignette and attend a SAS workshop on study. GROUP F (PROBLEM): Participants view the problem vignette and attend a SAS workshop on study.

Interventions

BEHAVIORALAssessment

Ancillary studies

View the chronically relapsing brain disease vignette

OTHERTraining

Attend a SAS workshop

Sponsors

Ohio State University Comprehensive Cancer Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Employee of Ohio State University Wexner Medical Center (OSUWMC) * Age ≥ 18 years * Participants must be able to read and comprehend survey items

Design outcomes

Primary

MeasureTime frameDescription
Stigmatizing attitudesBefore, immediately after and 8 weeks after the sessionStigmatizing attitudes will be measured with the Stigma and Attribution Assessment. The assessment score will be compared both between and within participants for each case vignette. Results will be reported with descriptive statistics, including means and standard deviations or medians and first-third quartiles for continuous variables, and frequencies and percentages for discrete variables.The linear mixed effect model will be used to study the repeated stigma and attribution measures over time (pre-workshop, immediately post-workshop, and 8 weeks post-workshop) within 6 vignettes as well as the effects between the vignettes, while controlling for the potential confounding factors (e.g., sex).

Secondary

MeasureTime frameDescription
Response to post-workshop evaluationsBefore, immediately following and 8 weeks after the session.The proportion of participants who respond to the post-workshop evaluations will be summarized with 95% confidence interval.
Attendance rateAt 90 minute session.The proportion of participants attending the workshop will be summarized with 95% confidence interval.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026